- Home
- GCTS vs CTSO Comparison
GCTS vs CTSO Comparison
Compare GCTS & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTS
- CTSO
- Stock Information
- Founded
- GCTS 1998
- CTSO 1997
- Country
- GCTS United States
- CTSO United States
- Employees
- GCTS N/A
- CTSO N/A
- Industry
- GCTS Blank Checks
- CTSO Medical/Dental Instruments
- Sector
- GCTS Finance
- CTSO Health Care
- Exchange
- GCTS Nasdaq
- CTSO Nasdaq
- Market Cap
- GCTS 73.7M
- CTSO 61.7M
- IPO Year
- GCTS N/A
- CTSO N/A
- Fundamental
- Price
- GCTS $1.62
- CTSO $0.93
- Analyst Decision
- GCTS Strong Buy
- CTSO Buy
- Analyst Count
- GCTS 1
- CTSO 2
- Target Price
- GCTS $5.00
- CTSO $5.50
- AVG Volume (30 Days)
- GCTS 260.1K
- CTSO 124.2K
- Earning Date
- GCTS 11-13-2025
- CTSO 11-06-2025
- Dividend Yield
- GCTS N/A
- CTSO N/A
- EPS Growth
- GCTS N/A
- CTSO N/A
- EPS
- GCTS N/A
- CTSO N/A
- Revenue
- GCTS $6,073,000.00
- CTSO $36,107,520.00
- Revenue This Year
- GCTS $133.55
- CTSO $11.93
- Revenue Next Year
- GCTS $347.37
- CTSO $21.22
- P/E Ratio
- GCTS N/A
- CTSO N/A
- Revenue Growth
- GCTS N/A
- CTSO 20.18
- 52 Week Low
- GCTS $0.90
- CTSO $0.71
- 52 Week High
- GCTS $3.45
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- GCTS 69.51
- CTSO 45.12
- Support Level
- GCTS $1.26
- CTSO $0.87
- Resistance Level
- GCTS $1.59
- CTSO $1.04
- Average True Range (ATR)
- GCTS 0.07
- CTSO 0.05
- MACD
- GCTS 0.03
- CTSO -0.00
- Stochastic Oscillator
- GCTS 96.10
- CTSO 34.66
About GCTS GCT Semiconductor Holding Inc. Common Stock
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.